Serum arginase activity in postsurgical monitoring of patients with colorectal carcinoma

BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with pr...

Full description

Saved in:
Bibliographic Details
Published in:Cancer 2002-06, Vol.94 (11), p.2930-2934
Main Authors: Porembska, Zofia, Skwarek, Anna, Mielczarek, Magdalena, Barańczyk‐Kuźma, Anna
Format: Article
Language:English
Subjects:
Adenocarcinoma - enzymology
Adenocarcinoma - secondary
Adenocarcinoma - surgery
Adult
Aged
arginase
Arginase - blood
Biological and medical sciences
Biomarkers, Tumor - blood
colorectal liver metastases
Colorectal Neoplasms - enzymology
Colorectal Neoplasms - pathology
Colorectal Neoplasms - surgery
Female
Gastroenterology. Liver. Pancreas. Abdomen
human colorectal carcinoma
Humans
Liver Neoplasms - enzymology
Liver Neoplasms - secondary
Liver Neoplasms - surgery
Male
Medical sciences
Middle Aged
Neoplasm Recurrence, Local - enzymology
Neoplasm Recurrence, Local - secondary
Neoplasm Recurrence, Local - surgery
Postoperative Care
Preoperative Care
Prognosis
serum marker
Stomach. Duodenum. Small intestine. Colon. Rectum. Anus
Tumors
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:BACKGROUND Colorectal carcinoma (CRC) is one of the most common malignancies. In the current work, the role of arginase as a diagnostic marker in patients with recurrent CRC and colorectal liver metastases (CRCLM) was studied. METHODS Arginase activity was monitored in serum from 40 patients with primary CRC and from 100 patients with CRCLM. Blood was taken before and after patients underwent tumor resection. Studies were conducted for 3 years. RESULTS Preoperative arginase activity in serum from patients with CRC and CRCLM was much greater compared with the arginase activity in serum from healthy control blood donors. One and two cut‐off levels of increased arginase activity were observed in patients with CRC and CRCLM, respectively. After patients underwent tumor resection, the arginase activity decreased to normal values in both patients with CRC and patients with CRCLM. Activity levels remained low in patients who did not develop recurrent CRC or CRCLM (first or second). In patients who developed subsequent recurrences or metastases that appeared after surgery, during 3 years of surveillance, a significant rise in serum arginase activity was observed. The clinical prognosis for patients was worst when the postoperative serum arginase activity was very high, because those patients more often developed second liver metastases or died. CONCLUSIONS The authors conclude that the determination of serum arginase activity may be a complementary test to confirm the occurrence of CRC and may be useful for the early diagnosis of patients who develop recurrent CRC and/or CRCLM. Cancer 2002;94:2930–4. © 2002 American Cancer Society. DOI 10.1002/cncr.10563 The determination of serum arginase activity may be a complementary test confirming the occurrence of colorectal carcinoma and can be useful for the early diagnosis of patients with recurrent colorectal carcinoma and/or liver metastases.
ISSN:0008-543X
1097-0142
DOI:10.1002/cncr.10563